Presented improved editing data in non-human primates (NHP) for sickle cell disease (SCD), demonstrating a single dose of Gene Writer achieved an average of 85% of long-term hematopoietic stem cells (LT-HSCs) with at least one allele edited on single cell analysis, exceeding the anticipated curative threshold Reported first demonstration of permanent chimeric antigen receptor (CAR) integration in NHP with a single dose of Gene Writer delivered as all-RNA in T cell-directed li

Dravet syndrome has long represented one of the most challenging pediatric epilepsies encountered in neurology and genetic medicine. Caused primarily by loss‑of‑function variants in SCN1A, the disorder emerges in infancy with prolonged febrile seizures and evolves into a lifelong condition marked by treatment‑resistant epilepsy, developmental delay, and significant morbidity. As the gene and cell therapy community gathers for the American Society of Gene and Cell Therapy (ASG

From big names such as Google and Anthropic to specialists like Abridge, World Labs, and Mithril, these companies are proving that AI’s ability to solve new problems is hardly tapped out. https://www.fastcompany.com/91495412/artificial-intelligence-most-innovative-companies-2026 Over the past year, tech companies invested hundreds of billions in the new data centers needed to power rapidly increasing demand for the technology. The investment is motivated in part by confidenc

Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression 14-Month Follow-up Data Show Hypoimmune (HIP)-Modified Islets are Safe, Evade Detection by the Immune System, Survive Long-Term, and Continue to Produce Insulin C-Peptide Levels at Month 14 Comparable to Initial Six Months of Study; Results Highlight the Importance of Improved Glycemic Control on Islet Function Full 14-Month Da

Generate Biomedicines has raised $400m in one of the largest biotech initial public offerings (IPO) since 2024, signalling renewed investor appetite for drug developers making the public jump. Generate, an AI drug discovery specialist, has priced 25 million shares at $16 each. The $400m could be bolstered by a further $60m if underwriters exercise their option to buy an additional 3.75 million shares at the same price. Generate’s stock will hit the Nasdaq Global Select Market

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. Under the leadership of CEO Marianne De Backer, Ph.D., Vir is trading a stake in its PSMA-targeted bispecific VIR-5500 for a $335 million upfront and near-term capital infusion from Astellas. The PSMAxCD3 bispecific leverages Vir’s PRO-XTEN dual-masking technology, which is designed to keep the therapy in

SOMERVILLE, Mass., February 23, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygou

SOMERVILLE, Mass., January 12, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics , the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TSRA-196, its lead in vivo gene editing therapy for alpha-1 antitrypsin deficiency (AATD). The Company has also received Australian Human Research Ethics Committee (HREC) approval

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting Manageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone pr